TxCell reviews its manufacturing strategy to focus on R&D and strategic partnerships
Company to outsource all existing and future clinical and commercial manufacturing operations.
TxCell is operating a strategic review that should result in the outsourcing of all existing and future clinical and commercial manufacturing operations to contract manufacturing organizations (CMOs).
The strategic review, which is being discussed with TxCell employee’s representatives, should enable TxCell to focus on its key strengths of research, clinical development and new partnerships. The Company will retain, as well as further strengthen its critical process development capabilities and GMP-proving activities with key recruitments and opening of a dedicated laboratory.
“The cellular therapy production sector is making significant progress in key specialized areas that are required by TxCell. There are now a number of CMOs globally that have the capability to operate reliably in the cellular therapy space,” said Stéphane Boissel, CEO of TxCell. “The reorganization proposed by TxCell should enable us to focus on key high-value creation activities that will also further accelerate our own development. Specifically, TxCell would concentrate on discovery, research, clinical development and manufacturing process improvement. We would then have the capability to bring at least three new products from its two platforms, including innovative Chimeric Antigen Receptor (CAR)-engineered Treg cell products, to clinical development within five years. This would result from a combination of stand-alone development and co-development with strategic partners.”
As a result of the proposed reorganization, TxCell intends to open a new, GMP-proving laboratory, based within or close to TxCell’s existing headquarters in Sophia Antipolis (France). This laboratory will finalize process improvement and development and ensure the transfer of technology to CMOs.
TxCell will seek CMO partnerships in EU, US and Asia for the GMP manufacturing of its clinical and commercial products. These partnerships will be in addition to existing relationships with MaSTherCell (BE) and Cell Therapy Catapult (UK), both based in Europe.
Following a consultation period for the employee’s representatives, TxCell intends to rapidly close its own Besançon pilot manufacturing facility. This has been designed to be a temporary site for TxCell. The Company is currently evaluating options for its local 26 employees that would be impacted by this closure.
“It is our responsibility to best help the impacted Besançon staff to rapidly find new job opportunities,” said Raphael Flipo, CFO of TxCell. “The employees in Besançon, who are all very qualified and well trained, have done an excellent job since the opening of the facility in 2013. Our decision to close the Besançon facility is only driven by strategic and economic considerations.”
The changes in TxCell manufacturing strategy should have no impact on the timelines for both Ovasave and Col-Treg clinical development. The CMO MaSTherCell is scheduled to start manufacturing batches of Ovasave in Q2 2016.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance